<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129432">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01899976</url>
  </required_header>
  <id_info>
    <org_study_id>Protocol Number BI-03-01</org_study_id>
    <nct_id>NCT01899976</nct_id>
  </id_info>
  <brief_title>X-MAS Biliary Study With Covered Biliary Stent</brief_title>
  <official_title>A Non-Randomized, Multi-Center, Prospective, Single Arm Clinical Study of the X-SUIT NIR® Covered Biliary Metallic Stent for Palliation of Malignant Strictures in the Biliary Tree Via Endoscopic Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medinol Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medinol Ltd.</source>
  <oversight_info>
    <authority>Netherlands:  Independent Ethics Committee</authority>
    <authority>Belgium: Ethics Committee</authority>
    <authority>France: National Consultative Ethics Committee for Health and Life Sciences</authority>
    <authority>Israel: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide safety and efficacy data for the X-Suit NIR® Covered
      Biliary Metallic Stent for subjects with malignant stricture(s) in the biliary tree. The
      study is designed to support the regulatory requirement of a 510(k) marketing application in
      the United States.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized, multi-center, prospective, single arm clinical study of the X-Suit
      NIR® Covered Biliary Metallic Stent for the palliation of malignant strictures in the
      biliary tree via endoscopic approach.

      Adult males and females (≥ 18 years old), with clinical symptoms of biliary obstruction and
      inoperable extrahepatic biliary obstruction by any malignant process.

      The expected duration of this study is approximately 18 months from the time of first
      subject enrollment to the time of the last subject's 6-month post stent implantation
      follow-up visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Maintenance of a total serum bilirubin level ≤ 3.0 mg/dL or a reduction of &gt;30% if baseline value was greater than 3.0 mg/dL</measure>
    <time_frame>6 months follow up or prior to death, whichever comes first</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>From date of stent implantation until the date of 6 month follow-up visit, or date of death, whichever comes first</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">68</enrollment>
  <condition>Malignant Strictures in the Biliary Tree</condition>
  <arm_group>
    <arm_group_label>X-Suit NIR Covered Biliary Stent</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Stent implantation in the biliary tree</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>X-Suit NIR Covered Biliary Stent</intervention_name>
    <arm_group_label>X-Suit NIR Covered Biliary Stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18 or older.

          2. Clinical symptoms of biliary obstruction.

          3. Presence of inoperable extrahepatic distal biliary obstruction by any malignant
             process (the subject not being a surgical candidate based on the finding of a
             pancreatic mass &gt;2.0cm or a severe medical illness).

          4. Subject is willing and able to comply with the study procedures and provide written
             informed consent to participate in the study.

          5. Insured by Social Security (applicable to subjects screened in France).

        Exclusion Criteria:

          -  1. Participation in an Investigational Study within 90 days prior to date of subject
             consent.

             2. Perforation of any duct within the biliary tree. 3. Presence of more than one
             previously implanted plastic stent. 4. Previous plastic stent implantation less than
             2 weeks prior to current procedure.

             5. Presence of a metal biliary stent. 6. Presence of any esophageal or duodenal
             stent. 7. Previous Bilroth II or Roux-en-Y gastric resection, a significant duodenal
             obstruction or any other altered anatomy which could prevent access to ampulla.

             8. Subjects for whom endoscopic procedures are contraindicated. 9. Subjects with
             known sensitivity to any components of the stent or delivery system.

             10. Subjects with active hepatitis or other hepatic diseases that may cause jaundice.

             11. Subjects with a WHO performance score of 4 - Bedbound (completely disabled,
             cannot carry on any self-care, totally confined to bed or chair).

             12. Subjects known to be pregnant.

        Cholangiographic exclusion criterion:

        13. Strictures that cannot be passed by the guide wire or the delivery system.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hôpital Erasme Brussels (ULB)</name>
      <address>
        <city>Brussels</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Le Moine, MD</last_name>
      <email>Olivier.Lemoine@erasme.ulb.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Mia Persoons</last_name>
      <phone>+32 2 555 3016</phone>
      <email>Mia.Persoons@erasme.ulb.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier Le Moine, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hillel Yafeh Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zvi Fireman, MD</last_name>
      <phone>972 4-6304680/6</phone>
    </contact>
    <contact_backup>
      <last_name>Elisabeth Mahagna</last_name>
      <phone>972 4-6304695</phone>
      <email>LiesMa@hy.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Zvi Fireman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>31096</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alain Suissa, MD</last_name>
      <phone>972 4-8543853</phone>
      <email>A_suissa@Rambam.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Dalia Catz</last_name>
      <phone>972 50-2062504</phone>
      <email>Dal_katz@rambam.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Alain Suissa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91031</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eran Goldin, MD</last_name>
      <phone>972 2-6666065</phone>
      <email>erang@szmc.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Chava Kaniel</last_name>
      <phone>972 2 6555916</phone>
      <email>chavak@szmc.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Eran Goldin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Haddasah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yael Kopelman, MD</last_name>
      <phone>972 50-5172800</phone>
      <email>YaelKo@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Shoshi Shpitzen</last_name>
      <phone>972 50-6441368</phone>
      <email>shpi@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Yael Kopelman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center, Tel Hashomer</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maor Lahav, MD</last_name>
      <phone>972 3-5302660</phone>
      <email>Maor.Lahav@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Neumann</last_name>
      <phone>972 52-3307575</phone>
      <email>neumansandra@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Maor Lahav, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>64239</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ervin Santo, MD</last_name>
      <phone>972 3-6974282</phone>
      <email>erwins@tlvmc.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Nataly B Shulman</last_name>
      <phone>972 52-4262649</phone>
      <email>natalybe@tlvmc.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Ervin Santo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <state>Heidelberglaan</state>
        <zip>100, 3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Peter Siersema, MD</last_name>
      <phone>+31 (0) 88 75 58175</phone>
      <email>P.D.Siersema@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Daisy Walter, MD</last_name>
      <phone>+31 887559338</phone>
      <email>D.Walter@umcutrecht.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Peter Siersema, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Academic Medical Center (AMC)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanin Van Hooft, MD</last_name>
      <phone>+312056679</phone>
      <email>j.e.vanhooft@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Selma Lekkerkerker</last_name>
      <email>s.j.lekkerkerker@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jeanin Van Hooft, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Israel</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>covered biliary stent</keyword>
  <keyword>X-Suit NIR Covered Biliary Stent</keyword>
  <keyword>malignant strictures in biliary tree</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
